In general, c-MYC rearranged B-cell lymphomas with a simple karyotype such as that usually seen in BL respond better to chemotherapy, while those with a complex karyotype, as is typically seen in DHLs, show a very poor clinical course and are refractory to conventional chemotherapy and even hematopoietic stem cell transplant. Here, MYC is linked to B-cell non-Hodgkin lymphoma.